The aim of this study was to clarify whether administration of antipsychotic perphenazine contributes to the electrophysiological changes of the isolated heart. Fourteen adult male Wistar rats were divided into two groups. Langendorff hearts were perfused with Krebs-Henseleit solution at constant pressure (85 mmHg) and 37 °C (CaCl 2 , 1.2 mM). The electrogram was recorded by touch-free method. The hearts of the first group were exposed to 3.10 -5 M perphenazine, the hearts of the second group to 3.10 -8 M perphenazine. The incidence of arrhythmias and the heart rate and QT interval changes were studied on electrogram during 30 min periods of control, the first perphenazine administration, washout, and the second drug administration.
Cardiovascular system disorders are among the most common causes of morbidity and mortality in developed countries. Many of them are caused by side effects of noncardiovascular drugs whose nature and mode of action vary greatly. A typical example is psychotropic drugs, substances with reported high incidence of cardiovascular side effects, often expressed as various electrophysiological changes. Their representative perphenazine has been used as a psychotropic drug for several decades in therapy of certain psychiatric disorders. It has been reported to induce asymptomatic ECG changes, tachyarrhythmias, self-terminating arrhythmias, or even ventricular fibrillation resulting in the cardiac arrest, especially when overdosed. There are no reports that perphenazine affects electrophysiological properties of the cardiac tissue at therapeutic doses, but, certain ECG changes were observed during its administration in the presence of other potentially arrhythmogenic factors (Magorien et al. 1979) .
In isolated cardiomyocytes, the effects of perphenazine is functionally related to a variety of ion membrane currents. It reversibly blocks fast sodium current I Na and transient outward potassium current I to . Sensitivity of I Na and I to to perphenazine lies in the micromolar range, whereas the therapeutic plasma concentrations are in the nanomolar range (Bébarová et al. 2009 ). In isolated rat hearts, perphenazine at concentrations highly above the clinically relevant range caused numerous ECG changes (Langslet 1970) .
Perphenazine-triggered cardiovascular side effects may be of various severities. Prolonged QT interval is supposed to be a marker for the drug arrhythmogenic capacity. Therefore, L-QT is of major concern; however, there is growing evidence that the link between QT prolongation and the risk of clinical events is poorly understood (Roden 2004) .
The aim of the present study was to clarify whether administration of perphenazine contributes to the electrophysiological changes also at nanomolar concentrations.
Materials and Methods

Experimental groups
Experiments were performed on 14 adult male Wistar rats (average b. m. 311 ± 33 g) divided randomly into two groups. The first group was exposed to the dose 3.10 -5 M of perphenazine similarly as by Langslet (1969 Langslet ( , 1970 . The second group was exposed to the dose 3.10 -8 M of perphenazine (plasma concentrations in treated patients; Omerov et al. 1989) . The drug was distributed via the coronary system into the isolated heart. Perphenazine (Sigma-Aldrich, Czech Republic) was dissolved in 96% ethanol to 10 -3 M stock solution. The final tested concentrations were obtained by subsequent dilution in saline solution. The final dose of ethanol was 5m M which was proved not to affect ion currents on the membrane of cardiomyocyte (Bébarová et al. 2010) .
All animal experiments were carried out with respect to the recommendations of the European Community Guide for the Care and Use of Laboratory Animals and followed the guidelines for animal treatment approved by local authorities.
Isolated heart preparation
Animals were deeply anaesthetized with ether and their chest was opened. The heart was quickly excised and placed in cold bath containing Krebs-Henseleit (K-H) solution. The aorta was immediately cannulated, the heart was fixed to Langendorff set-up modified for pharmacological studies (Nováková et al. 2000) and perfused at constant pressure (85 mmHg) and 37 °C with K-H solution, (in mM: 118 NaCl, 4.7 KCl, 25.0 NaHCO 3 , 7 glucose, 1.2 KH 2 PO 4 , 1.2 MgSO 4 and 1.25 CaCl 2 ) continuously aerated (95% O 2 , 5% CO 2 ) . The heart was placed in a thermostatically-controlled bath filled with K-H solution. The coronary effluent was continuously drained from the bath by overflow.
The experiment consisted of four 30 min periods: control, the first perphenazine administration, washout, and the second perphenazine application.
Electrograms were continually recorded from three orthogonal bipolar leads (X, Y, and Z) by the touch-free method (Nováková et al. 2000) .
Data analysis
The recorded signals were stored and subsequently analysed. RR and QT intervals were measured and the incidence of arrhythmias was counted. RR intervals were averaged at the end of the control period (steady state heart rate) and the normalized heart rate (HR) was calculated. In the same way, QT intervals were evaluated and subsequently corrected to particular HR and expressed as rate-corrected QT (QT c , Kawataki's formula). The severity of arrhythmias was assessed according to Lambeth Conventions (Walker et al. 1988) . Premature ventricular complexes (PVCs) were counted as well as the number of episodes of ventricular tachycardia (VT) and ventricular fibrillation (VF). Each heart was given a s.-c. Lambeth score -from 0 to 5 (0 -no arrhythmia, 1 -single PVCs, 2 -salvos, 3 -VT, 4 -reversible VF, 5 -sustained VF).
The mean coronary flow was estimated every 5 min during the experiment.
Statistical analysis of the HR and QT intervals Standard descriptive statistics both parametric and non-parametric were used for the description of each phase (mean, median, range). The differences between consecutive phases of the experiment were analysed by means of paired t-test. The differences between individual phases of each experiment and its control period were analysed by means of one sample t-test. Paired t-test was used for comparisons between the effects of groups 1 and 2 and to determine the significance of HR changes, QT interval prolongation and coronary flow evoked by perphenazine against the initial values for each drug dose. The time distribution of PVCs was analysed by Mann-Whitney U test.
Results
Heart rate
Normalized values of HR in both concentrations showed decreasing tendency. HR in group 1 (10 -6 M) (Fig. 1) significantly declined during the first perphenazine period to 92% (p < 0.05, compared to control values), in the subsequent drug application, slightly decreased to 88%. In group 2 similar changes were found, however nonsignificant. Normalized HR decreased to 94% at the end of the experiment.
QT interval
In group 1, significant (p < 0.001) prolongation of QT interval (by 20%) was observed after the first drug application (Fig.  2) . During the second drug administration significantly prolonged to 114% of control values. In group 2, perphenazine caused much weaker changes than those in group 1. QT prolongation was significant only during the first perphenazine administration (p < 0.05). Significant prolongation of QTc after both perphenazine concentrations was observed and this change was fully reversible (Fig. 3) .
Incidence of arrhythmias
Exposure of isolated rat hearts to perphenazine brought about various arrhythmias, from single PVCs to salvos and, eventually, VT. The occurrence of arrhythmias showed remarkable discrepancy between groups 1 and 2 in terms of the number and distribution of arrhythmias. In group 1, mainly PVCs appeared. They were observed during the first perphenazine administration, but surprisingly increased to a maximum during the washout (p < 0.05). During the second perphenazine exposure only two episodes of VT and two episodes of PVCs occurring as salvos were recorded (Fig. 4) . The total number of PVCs counted as single PVCs or part of tachyarrhythmias was 191. In group 2, arrhythmias completely disappeared during washout and reappeared after the second perphenazine administration (Fig. 4) . Moreover, the total number of PVCs in group 2 was 291. During the second perphenazine administration, the highest incidence of PVCs, present as single ones or as part of 15 episodes of VT, was observed.
The comparison of the Lambeth score in both groups revealed that 3 hearts from group 1 and one from group 2 reached the score 0 (i.e. no arrhythmias). Score 1 was found in 2 hearts in group 1 and in 5 hearts in group 2. Score 3 (VT) was found in 2 hearts from group 1 and one from group 2.
Coronary flow
Mean coronary flow served only as a subsidiary indicator. It did not change significantly after the perphenazine administration in either experimental group.
Discussion
The widespread overuse of drugs represents a certain risk due to the adverse side effects, drug cumulation and interactions. A frequent target of these side effects is the electrical stability of the heart.
In agreement with data of Langslet (1969 Langslet ( , 1970 we proved that higher concentration of perphenazine leads to significant prolongation of QT interval. In the present study, the direct changes of QT interval following exposure to nanomolar concentrations of perphenazine were similar to those characterized by Langslet at micromolar concentration.
Moreover, insignificant decrease of HR at both concentrations was observed. The HR decay after exposure to the higher concentration was more pronounced. This finding is also in agreement with Langslet's results concerning a dose dependent decrease in cardiac impulse generation and conduction velocity induced by different phenothiazines among which perphenazine appeared to be one of the most efficient (Langslet 1970) .
Thus, the most important finding of this study is that perphenazine significantly prolongs the QT interval and triggers arrhythmias in considerable numbers both at the high concentration and at the therapeutical concentration. This proarrhythmogenic effect is observed even after repeated exposure to perphenazine.
Prolonged QT interval may degenerate into malignant ventricular arrhythmias such as torsade de pointes (TdP), VF or cardiac arrest. Case-control studies and epidemiological data show increased incidence of sudden cardiac death in psychiatric patients taking antipsychotics (Hennessy et al. 2002) . Other studies have revealed the potential of several phenothiazines to induce acquired L-QT syndrome, with prolonged QT c intervals and a high risk for both TdP and sudden cardiac death (Reilly et al. 2000) . Nevertheless, the therapeutic potential of perphenazine is considered high and its use for the treatment of specific clinical situations is justified.
With respect to the abovementioned facts, we evaluated the incidence of arrhythmias in our model. The most interesting finding is the difference in total number and time distribution of arrhythmias during the experiment, namely, the maximum occurrence of PVCs during the second perphenazine application in the low concentration group.
A number of antipsychotics including perphenazine were identified as substances that affect sigma receptors in various tissues. They are a type of non-opioid binding sites and were reported in various tissues (Su and Junien 1994) , including the heart muscle (Novakova et al. 1995) . Perphenazine belongs to prototypic sigma receptor ligands.
Our previous studies have been mostly performed using another sigma receptor ligand haloperidol at clinically relevant nanomolar concentrations. Arrhythmias of various severities following acute exposure to haloperidol appeared and vanished after prolonged exposure to haloperidol. It may be explained in terms of desensitization or down-regulation of sigma receptors (Fialova et al. 2009 ). However, our present data on incidence of arrhythmias during repeated administration of perphenazine in isolated rat heart cannot be simply explained in this way. Different total numbers of arrhythmias and also dissimilar time distribution of PVCs at the two tested concentrations indicate that this compound may act through different routes. Nevertheless, this finding deserves further examination.
Účinky perfenazinu studované na modelu izolovaného srdce potkana
Cílem práce bylo posoudit možné změny elektrofyziologických vlastností srdce po akutní aplikaci perfenazinu v nanomolárních a mikromolárních koncentracích. Byl hodnocen výskyt arytmií, změny srdeční frekvence a délky QT intervalu na modelu izolovaného srdce potkana. Do experimentu bylo zařazeno 14 samců laboratorního potkana Wistar, rozdělených na skupinu 1 (3.10 -5 M perfenazin) a 2 (3.10 -8 M perfenazin). Izolovaná srdce byla perfundována podle Langendorffa Krebs-Henseleitovým roztokem (CaCl 2 , 1.2 mM) za konstantního tlaku (85 mmHg) a teploty 37 °C. Experiment byl rozdělen na čtyři úseky (30 min): kontrola, první aplikace perfenazinu, výplach, druhá aplikace perfenazinu. V prů-běhu celého experimentu byl bezdotykovou metodou registrován elektrogram.
Po aplikaci perfenazinu došlo ve skupině 1 k signifikantnímu prodloužení QT (p < 0.001) a QTc (p < 0.05). Ve skupině 2 došlo k prodloužení QT a QTc na hladině významnosti p < 0.05. U obou skupin zvířat se po akutní expozici perfenazinu objevily arytmie různé závažnosti. Změny srdeční frekvence byly nesignifikantní.
Fenothiaziny jsou stále lékem volby u některých akutních i chronických psychóz. Jejich vedlejší účinky na kardiovaskulární systém by však měly být vždy brány v úvahu.
